

# World Journal of *Orthopedics*

*World J Orthop* 2023 April 18; 14(4): 171-267



**REVIEW**

- 171 Meniscus tears treatment: The good, the bad and the ugly-patterns classification and practical guide  
*Simonetta R, Russo A, Palco M, Costa GG, Mariani PP*

**MINIREVIEWS**

- 186 Effects of different pelvic osteotomies on acetabular morphology in developmental dysplasia of hip in children  
*Wen Z, Wu YY, Kuang GY, Wen J, Lu M*
- 197 Background, techniques, applications, current trends, and future directions of minimally invasive endoscopic spine surgery: A review of literature  
*Tang K, Goldman S, Avrumova F, Lebl DR*

**ORIGINAL ARTICLE****Basic Study**

- 207 Bridge plating in the setting of radiocarpal instability: Does distal fixation to the second or third metacarpal matter? A cadaveric study  
*Tabeyo E, Saucedo JM, Srinivasan RC, Shah AR, Karamanos E, Rockwood J, Rodriguez-Merchan EC*

**Retrospective Cohort Study**

- 218 Clinical outcomes of cemented distal femur replacements with all-polyethylene tibial components for oncologic indications  
*Christ AB, Chung BC, Urness M, Mayer LW, Gettleman BS, Heckmann ND, Menendez LR*
- 231 Acute hospital-community hospital care bundle for elderly orthopedic surgery patients: A propensity score-matched economic analysis  
*Tan IEH, Chok AY, Zhao Y, Chen Y, Koo CH, Aw J, Soh MHT, Foo CH, Ang KA, Tan EJKW, Tan AHC, Au MKH*

**Retrospective Study**

- 240 Knowledge and attitudes of orthopedic surgeons regarding prosthesis joint infection  
*Aytekin MN, Hasanoglu I, Öztürk R, Tosun N*

**Observational Study**

- 248 Perceived barriers and facilitators of day-case surgery for major foot and ankle procedures? A cross-sectional survey of United Kingdom surgeons  
*Berry A, Houchen-Wolloff L, Crane N, Townshend D, Clayton R, Mangwani J*

**CASE REPORT**

- 260 Subclinical ankle joint tuberculous arthritis - The role of scintigraphy: A case series  
*Primadhi RA, Kartamihardja AHS*

**ABOUT COVER**

Editorial Board Member of *World Journal of Orthopedics*, Saubhik Das, MS, Assistant Professor, Department of Orthopaedics, Rajendra Institute of Medical Sciences, Ranchi 834009, Jharkhand, India. drsaubhikk@hotmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Orthopedics (WJO, World J Orthop)* is to provide scholars and readers from various fields of orthopedics with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJO* mainly publishes articles reporting research results and findings obtained in the field of orthopedics and covering a wide range of topics including arthroscopy, bone trauma, bone tumors, hand and foot surgery, joint surgery, orthopedic trauma, osteoarthritis, osteoporosis, pediatric orthopedics, spinal diseases, spine surgery, and sports medicine.

**INDEXING/ABSTRACTING**

*WJO* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJO* as 0.62. The *WJO*'s CiteScore for 2021 is 2.4 and Scopus CiteScore rank 2021: Orthopedics and Sports Medicine is 139/284.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

**NAME OF JOURNAL**

*World Journal of Orthopedics*

**ISSN**

ISSN 2218-5836 (online)

**LAUNCH DATE**

November 18, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Massimiliano Leigheb

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/2218-5836/editorialboard.htm>

**PUBLICATION DATE**

April 18, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**


<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Retrospective Cohort Study

# Clinical outcomes of cemented distal femur replacements with all-polyethylene tibial components for oncologic indications

Alexander B Christ, Brian C Chung, Matthew Urness, Lucas W Mayer, Brandon S Gettleman, Nathanael D Heckmann, Lawrence R Menendez

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Gutowski CJ, United States; Mohammadpour M, Iran

**Received:** January 13, 2023

**Peer-review started:** January 13, 2023

**First decision:** February 2, 2023

**Revised:** February 10, 2023

**Accepted:** April 4, 2023

**Article in press:** April 4, 2023

**Published online:** April 18, 2023



**Alexander B Christ, Brian C Chung, Matthew Urness, Lucas W Mayer, Nathanael D Heckmann, Lawrence R Menendez,** Department of Orthopedic Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States

**Brandon S Gettleman,** University of South Carolina School of Medicine, Columbia, SC 29209, United States

**Corresponding author:** Alexander B Christ, MD, Doctor, Department of Orthopedic Surgery, Keck School of Medicine of University of Southern California, 1500 San Pablo Street, Los Angeles, CA 90033, United States. [alexander.b.christ@gmail.com](mailto:alexander.b.christ@gmail.com)

## Abstract

### BACKGROUND

Endoprosthetic distal femoral replacement (DFR) is a well-established salvage procedure following resection of malignant tumors within the distal femur. Use of an all-polyethylene tibial (APT) component is cost-effective and avoids failure due to locking-mechanism issues and backside wear, but limits modularity and the option for late liner exchange. Due to a paucity of literature we sought to answer three questions: (1) What are the most common modes of implant failure for patients undergoing cemented DFR with APT for oncologic indications? (2) What is the survivorship, rate of all-cause reoperation, and rate of revision for aseptic loosening of these implants? And (3) Is there a difference in implant survivorship or patient demographics between cemented DFRs with APT performed as a primary reconstruction *vs* those performed as a revision procedure?

### AIM

To assess outcomes of cemented DFRs with APT components used for oncologic indications.

### METHODS

After Institutional Review Board approval, a retrospective review of consecutive patients who underwent DFR between December 2000 to September 2020 was performed using a single-institutional database. Inclusion criteria consisted of all patients who underwent DFR with a GMRS® (Global Modular Replacement System, Stryker, Kalamazoo, MI, United States) cemented distal femoral endoprosthesis and APT component for an oncologic indication. Patients

undergoing DFR for non-oncologic indications and patients with metal-backed tibial components were excluded. Implant failure was recorded using Henderson's classification and survivorship was reported using a competing risks analysis.

## RESULTS

55 DFRs (55 patients) with an average age of  $50.9 \pm 20.7$  years and average body mass index of  $29.7 \pm 8.3$  kg/m<sup>2</sup> were followed for  $38.8 \pm 54.9$  mo (range 0.2-208.4). Of these, 60.0% were female and 52.7% were white. The majority of DFRs with APT in this cohort were indicated for oncologic diagnoses of osteogenic sarcoma ( $n = 22$ , 40.0%), giant cell tumor ( $n = 9$ , 16.4%), and metastatic carcinoma ( $n = 8$ , 14.6%). DFR with APT implantation was performed as a primary procedure in 29 patients (52.7%) and a revision procedure in 26 patients (47.3%). Overall, twenty patients (36.4%) experienced a postoperative complication requiring reoperation. The primary modes of implant failure included Henderson Type 1 (soft tissue failure,  $n = 6$ , 10.9%), Type 2 (aseptic loosening,  $n = 5$ , 9.1%), and Type 4 (infection,  $n = 6$ , 10.9%). There were no significant differences in patient demographics or rates of postoperative complications between the primary procedure and revision procedure subgroups. In total, 12 patients (21.8%) required a revision while 20 patients (36.4%) required a reoperation, resulting in three-year cumulative incidences of 24.0% (95%CI 9.9%-41.4%) and 47.2% (95%CI 27.5%-64.5%), respectively.

## CONCLUSION

This study demonstrates modest short-term survivorship following cemented DFR with APT components for oncologic indications. Soft tissue failure and endoprosthetic infection were the most common postoperative complications in our cohort.

**Key Words:** Distal femoral replacement; Modular; Revision; Dislocation; Oncologic

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The current study demonstrates modest short-term survivorship following cemented distal femoral replacement with all-polyethylene tibial components for oncologic indications. Approximately one third of patients experienced a postoperative complication. The most common modes of implant failure were soft tissue failure and endoprosthetic infection.

**Citation:** Christ AB, Chung BC, Urness M, Mayer LW, Gettleman BS, Heckmann ND, Menendez LR. Clinical outcomes of cemented distal femur replacements with all-polyethylene tibial components for oncologic indications. *World J Orthop* 2023; 14(4): 218-230

**URL:** <https://www.wjgnet.com/2218-5836/full/v14/i4/218.htm>

**DOI:** <https://dx.doi.org/10.5312/wjo.v14.i4.218>

## INTRODUCTION

### Background

Endoprosthetic reconstruction of the distal femur has been used as a limb-salvage procedure to treat oncologic processes of the distal femur for nearly five decades[1], and is currently considered standard of practice for this indication. Improvements in design, such as a rotating hinge mechanism and ongrowth collars adjacent to the femoral cut surface, have improved survivorship with regards to aseptic loosening, and are now included in most modern systems[2-4]. However, implant design and research regarding fixation has focused primarily on the femoral side[5-7].

### Rationale

Metal-backed and all-polyethylene tibial components are available, both of which can be fixed to the bone with fully cemented, hybrid, or in some cases cementless fashion. However, there is a paucity of literature examining the survivorship of distal femoral replacements (DFRs) with respect to the type of tibial component or fixation used[8,9]. Furthermore, the majority of available studies fail to describe the type of tibial component or fixation used[10,11]. Therefore, the purpose of this study is to assess outcomes of cemented DFRs with all-polyethylene tibia (APT) components used for oncologic indications.

Specifically, we sought to answer the following research questions: (1) What are the most common modes of implant failure for patients undergoing cemented DFR with APT for oncologic indications? (2) What is the survivorship, rate of all-cause reoperation, and rate of revision for aseptic loosening of these implants? and (3) Is there a difference in implant survivorship or patient demographics between cemented DFRs with APT performed as a primary reconstruction *vs* those performed as a revision procedure?

## MATERIALS AND METHODS

### **Study design and participants**

After Institutional Review Board approval (IRB HS-20-00396), a retrospective review of consecutive patients who underwent DFR between December 2000 to September 2020 was performed using a single-institutional database. The DFR was performed either as the primary treatment for the disease in question, or as a revision of a previous failed surgery (indications included recurrence, fracture, *etc.*). We then defined reoperation as any subsequent procedure, including manipulation under anesthesia, that was performed after placement of the DFR. Revision of the DFR was defined as a subsequent procedure which specifically required exchange or removal of femoral or tibial components. Inclusion criteria consisted of all patients who underwent DFR with a GMRS® (Global Modular Replacement System, Stryker, Kalamazoo, MI, United States) cemented distal femoral endoprosthesis and APT component for an oncologic indication. Patients were excluded if undergoing DFR for non-oncologic indications or if a different implant design was used. Patients were then stratified into two groups based on whether the index procedure was a primary reconstruction or a revision of a previous DFR. Patients who had undergone previous incisional biopsies or arthroscopic procedures without reconstruction on the operative limb prior to DFR implantation were classified in the primary reconstruction cohort.

Thorough review of patient medical records and operative reports was performed to obtain patient demographic information including comorbidities, age at the time of surgery, sex, race/ethnicity, body mass index (BMI), and American Society of Anesthesiologists score. Operative reports were reviewed to obtain surgical variables including the indication for surgery, a comprehensive surgical history of the operative limb, surgical approach, implants utilized, and operative time. The primary outcome was implant survivorship, with all-cause reoperation and revision total knee arthroplasty as endpoints. Given the primary purpose of the present study was to characterize early complications and implant longevity in the setting of limb-salvage, functional and patient-reported outcome measures were not collected.

### **Implant design**


The Stryker GMRS® (Global Modular Replacement System, Stryker, Kalamazoo, MI, United States) was utilized for all cases in this series. This system is designed to assist in the reconstruction of large segmental and osteoarticular defects about the knee joint, particularly in the setting of tumors, previously failed arthroplasty, and traumatic injury. In this system, the standard distal femoral components can be paired with either a modular rotating-hinge tibial baseplate or APT component, the latter of which was used selectively in the present cohort (Figure 1). Multiple cemented stem options are available, including straight, curved, and long curved geometries, both with and without extra-cortical porous-coated intercalated body sections. This construct can be further customized with the use of extension pieces, available in over a dozen sizes, for the optimization of leg length.

### **Surgical technique**

Medial and lateral parapatellar approaches were utilized based upon previous biopsy incisions and location of the neoplasm. Following oncologic resection, the femur and tibia were prepared using conventional jigs and reamers, and the femur was reamed in a sequential manner to accommodate the appropriate stem diameter and length. Trial implants were inserted to assess appropriate range of motion, limb length, and patellar tracking prior to insertion of the final implant. Polymethylmethacrylate cement was used for fixation in all cases.

### **Clinical follow-up**

Each patient's clinical course was followed in detail to characterize postoperative complications and the need for reoperations or revision surgery. Given the complex patient demographics, we decided to not have a minimum follow-up in order to capture all patients who underwent this reconstruction. No follow-up was chosen over the conventional two-year minimum to capture early postoperative complications in this high-risk cohort of patients undergoing limb-salvage procedures, especially those with metastatic disease or prior failed reconstruction. Following the index procedure, any procedure on the affected limb that did not involve removal or alteration of the endoprosthesis was classified as a reoperation. Revision procedures were defined as any surgery involving removal or replacement of any prosthetic component. Implant failure was categorized based on the Henderson classification of failure



DOI: 10.5312/wjo.v14.i4.218 Copyright ©The Author(s) 2023.

**Figure 1 Radiographs of a 28-year-old male patient demonstrating a pathologic fracture of the distal third of the left femoral diaphysis. A:** Preoperative anteroposterior and lateral radiographs prior to reconstruction; **B:** Following left distal femoral replacement with use of an all-polyethylene tibial component.

of limb salvage after reconstructive surgery for bone tumors[12].

### Patient demographics and operative variables

In total, 92 patients were identified during the study period and screened for inclusion. Eleven patients (12.0%) with a metal-backed tibial baseplate and 26 patients (28.3%) who underwent DFR for a non-oncologic indication were excluded, leaving 55 patients (59.8%) who were included in the final analysis. The mean age of the cohort was  $50.9 \pm 20.7$  years (range, 16-88 years) and mean BMI was  $29.7 \pm 8.3$  kg/m<sup>2</sup> (range, 16.4-52.9). The average follow-up of the study cohort was  $38.8 \pm 54.9$  mo (range 0.2-208.4 mo), with a total of 21 patients (38.2%) possessing a minimum follow-up of 2 years (Table 1).

DFR with APT implantation was performed as a primary procedure in 29 patients (52.7%) and a revision procedure in 26 patients (47.3%), with a median operative time of 178 minutes across the entire cohort. For the 26 patients who underwent DFR with APT implantation as a revision procedure, the average number of previous surgeries on the affected limb was  $2.0 \pm 1.3$  (range 1-5) (Table 2). The primary procedures for the revision were as follows: distal femoral replacement[12], open reduction internal fixation for pathologic fracture[6], Cryoablation +/- curettage[6], and soft tissue resection[2] (Table 3). The majority of DFRs with APT in this cohort were indicated for oncologic diagnoses of osteogenic sarcoma ( $n = 22$ , 40.0%), giant cell tumor ( $n = 9$ , 16.4%), and metastatic carcinoma ( $n = 8$ , 14.6%) (Table 2).

### Statistical analysis

Statistical analyses were performed using SPSS version 26 (IBM, Armonk, New York, United States). Patient demographics, operative variables, and postoperative complications are presented as means or percentages with standard deviations or ranges where appropriate. Univariate analyses were performed to compare differences between groups using the Mann-Whitney-*U* test for continuous variables and Chi-square test for categorical variables or Fisher's exact test where appropriate. Competing risk analyses were performed to evaluate the cumulative incidence of all-cause reoperation, need for revision surgery, and patient death. Competing risk analysis was conducted using the survival[13,14] and cmprsk[15] function within R (R Core Team, 2021 packages)[16]. Figure 2 and Figure 3 were produced using the package ggplot2[17,18].

## RESULTS

### Modes of implant failure (Henderson classification)

In total, 20 patients (36.4%) experienced a postoperative complication requiring reoperation (Figure 4). The indications for the 26 reoperations were the following: Mechanical failure[11], non-union of prior pathologic fracture[7], tumor progression[3], definitive management of a prior open reduction internal fixation for a pathologic fracture[2], local recurrence[1], infection[1], and soft tissue failure[1] (Table 4). Of these 20 cases requiring reoperation, 7 patients (12.7%) required only one reoperation, 2 patients (3.6%) required 2 reoperations, 4 patients (7.3%) required 3 reoperations, and 7 patients (12.7%) required 4+ reoperations. The primary modes of implant failure in this cohort according to Henderson's classification included Type 1 (soft tissue failure,  $n = 6$ , 10.9%), Type 2 (aseptic loosening,  $n = 5$ , 9.1%), and

**Table 1 Patient demographics of the study cohort, including age, gender, race/ethnicity, American Society of Anesthesiologists score, body mass index, and length of follow-up, *n* (%)**

Demographic variable	Value
Age (mean ± SD)	50.9 ± 20.7 yr
Gender	
Male	22 (40.0)
Female	33 (60.0)
Race/Ethnicity	
White	29 (52.7)
Hispanic or Latino	9 (16.4)
Black	4 (7.3)
Asian	5 (9.1)
Other	8 (14.5)
ASA score	
1	10 (18.2)
2	21 (38.2)
3	21 (38.2)
4	3 (5.5)
Body mass index (mean ± SD)	29.7 ± 8.3 kg/m <sup>2</sup>
Follow-up (mean ± SD)	38.8 ± 54.9 mo

ASA: American Society of Anesthesiologists.

Type 4 (infection, *n* = 6, 10.9%) (Table 2). Of the 6 patients with a soft tissue failure, 3 were due to arthrofibrosis, 2 due to extensor mechanism failures, and one was due to wound dehiscence. Regarding the patients who failed due to infection, none of the individuals were on chemotherapy when infection was identified. Finally, local recurrence of the primary bone tumor occurred in one patient who was diagnosed with a “neoplasm of unspecified behavior” and was managed with radical resection at 13.2 mo (Henderson Type 5).

Of the five patients who required reoperation for soft tissue failure (Henderson Type 1), two patients experienced arthrofibrosis requiring manipulation under anesthesia with lysis of adhesions at 3.3 and 4.0 mo postoperatively, two patients required extensor mechanism repair for postoperative falls at 14.5 and 19.7 mo postoperatively, and one patient required multiple flaps for soft tissue reconstruction at 6.8 mo postoperatively. All six patients who underwent reoperation for infection (Henderson Type 4) were managed with serial irrigation and debridement procedures (mean 2.2 procedures, range 1-5), with two patients requiring antibiotic spacer placement and three patients undergoing soft tissue reconstruction at the time of reoperation. None of these patients required amputation.

Additionally, two patients required revision surgery for corrosion and metal wear debris at 32.5 mo and 99.5 mo postoperatively (Type 3). Two cases were complicated by deep peroneal nerve palsy, which were managed nonoperatively with ankle-foot orthoses. There were no identified cases for which periprosthetic fracture was the primary indication for revision surgery with the use of these constructs.

### Competing risks analysis

Competing risks analysis depicting the need for any revision operation (requiring exchange of either the femoral or tibial component), any reoperation, and patient death were plotted (Figure 3). In total, 12 patients (21.8%) required a revision, resulting in one- and three-year cumulative incidence of 14.6% (95%CI 5.7%-27.4%) and 24.0% (95%CI 9.9%-41.4%), respectively, with all-cause revision as the endpoint. Additionally, 20 patients (36.4%) required reoperation, resulting in one- and three-year cumulative incidences of 26.1% (95%CI 14.2%-39.7%) and 47.2% (95%CI 27.5%-64.5%), respectively, with all-cause reoperation as the endpoint. At final follow-up, one patient (1.8%) had died, with cause of death unrelated to the DFR procedure. No information regarding the date of death was available for this patient.

In total, 10 of the 12 patients (83.3%) who underwent revision surgery required revision of the APT component. Of these 10 patients, three (30.0%) were revised due to aseptic loosening at an average of

**Table 2 Operative variables of the study cohort, including procedure type (primary vs revision), surgical indications, mode of failure according to the Henderson Classification, and number of previous knee surgeries on the operative knee, *n* (%)**

Operative variable	Value
Procedure type	
Primary	29 (52.7)
Revision	26 (47.3)
Surgical indications	
Osteogenic sarcoma	22 (40.0)
Giant cell tumor	9 (16.4)
Metastatic carcinoma	8 (14.6)
Soft-tissue sarcoma <sup>a</sup>	4 (7.3)
Chondrosarcoma	
High-grade	3 (5.5)
Low-grade	2 (3.6)
Synovial chondromatosis	2 (3.6)
Multiple myeloma	2 (3.6)
Non-Hodgkin's lymphoma	1 (1.8)
Pigmented villonodular synovitis	1 (1.8)
Neoplasm of unspecified behavior	1 (1.8)
Primary mode of failure, henderson classification	
Type 1 (soft-tissue failure)	6 (10.9)
Type 2 (aseptic loosening)	5 (9.1)
Type 3 (structural failure) <sup>b</sup>	2 (3.6)
Type 4 (periprosthetic infection)	6 (10.9)
Type 5 (tumor progression)	1 (1.8)
Number of previous surgeries (mean ± SD)	1.1 ± 1.3 surgeries

<sup>a</sup>Soft-tissue sarcomas included malignant fibrous histiocytoma, pleomorphic fibrosarcoma, and myxofibrosarcoma.

<sup>b</sup>Both cases of henderson type 3 failure were due to trunnionosis; there were no periprosthetic fractures observed in this cohort.


**Table 3 Primary procedures for individuals requiring a revision distal femoral replacement**

Primary procedure in the revision cohort (N = 26)	
Category	Number of patients
Distal femoral replacement	12
Open reduction internal fixation for pathologic fracture	6
Curettage +/- cryoablation	6
Soft tissue resection	2

80.4 mo postoperatively, six (60.0%) were revised due to periprosthetic joint infection at an average of 44.8 mo, and one (10.0%) was revised due to periprosthetic fracture requiring placement of medial and lateral titanium plates at 9.6 mo. A second competing risks analysis depicting the incidence of all-cause revision of the APT component and APT component failure secondary to periprosthetic joint infection (PJI) was plotted (Figure 3). This analysis demonstrated one- and three-year cumulative incidences of 18.2% (95%CI 2.5%-45.5%) and 47.0% (95%CI 15.1%-74.0%), respectively, with all-cause revision of the APT component as the endpoint. When failure of the APT secondary to PJI was used as the endpoint, the one- and three-year cumulative incidences were 10.0% (95%CI 0.5%-37.4%) and 44.0% (95%CI 6.3%-59.3%), respectively.

**Table 4 Indication groupings for individuals requiring revision distal femoral replacement**

Reason for revision	
Category	Number of patients
Mechanical failure	11
Nonunion of prior pathological fracture	7
Tumor Progression	3
Definitive management of a prior open reduction internal fixation for a pathological fracture	2
Local recurrence	1
Infection	1
Soft tissue failure	1



**Figure 2 Competing risk analysis for cemented distal femoral replacement with all-polyethylene tibial component constructs for oncologic indications with all-cause revision (femoral or tibial component) and all-cause reoperation as the primary endpoints.** One- and three-year cumulative incidences were 14.6% (95%CI 5.7%-27.4%) and 24.0% (95%CI 9.9%-41.4%), respectively, with all-cause revision as the endpoint. One- and three-year cumulative incidences were 26.1% (95%CI 14.2%-39.7%) and 47.2% (95%CI 27.5%-64.5%), respectively, with all-cause reoperation as the endpoint. DFR: Distal femoral replacement.

**Univariate analysis**

No significant differences in patient demographics or reoperation rates were identified between patients for whom the index procedure was a primary reconstruction (“primary DFR”) and patients for whom DFR was performed as a revision procedure (“revision DFR”). Both cohorts had similar lengths of clinical follow-up ( $42.7 \pm 61.4$  vs  $34.5 \pm 47.5$  mo,  $P = 0.946$ ) (Table 5).


**DISCUSSION**

Endoprosthetic reconstruction is standard-of-care for oncologic processes of the distal femur, as greater than 90% of patients can be treated with limb salvage. While this procedure is effective in restoring mobility and salvaging the limb, it has a well-known complication and survival profile[19]. Aside from septic failure, aseptic loosening has been the leading cause of failure historically, and improvements have been focused on fixation of the femoral component[5,10]. However, relatively little attention has been paid to the tibial component. Unlike the femoral component, tibial components are available in both metal and all-polyethylene, and fixation of the tibial component can be achieved in a variety of ways, including cemented, cementless, and hybrid fixation. Despite the increased utilization of DFR

**Table 5 Univariate analysis comparing demographic characteristics and reoperation rates between the primary distal femoral replacement and revision distal femoral replacement subgroups, *n* (%)**

	Primary DFR ( <i>n</i> = 29)	Revision DFR ( <i>n</i> = 26)	<i>P</i> value
Age (mean ± SD)	49.7 ± 20.6 yr	52.2 ± 21.1 yr	0.649
Gender			0.44
Male	13 (44.8)	9 (34.6)	
Female	16 (55.2)	17 (65.4)	
Body mass index (mean ± SD)	29.5 ± 8.5 kg/m <sup>2</sup>	30.0 ± 8.4 kg/m <sup>2</sup>	0.567
Follow-up (mean ± SD)	42.7 ± 61.4 mo	34.5 ± 47.5 mo	0.946
Complication requiring reoperation?	11 (37.9)	9 (34.6)	0.799
Total reoperations required (mean ± SD)	1.4 ± 2.6	1.0 ± 1.8	0.624


DFR: Distal femoral replacement.



**Figure 3 Competing risk analysis for cemented distal femoral replacement with all-polyethylene tibial components for oncologic indications with all-cause revision of the all-polyethylene tibial component (APT) and revision of the APT due to periprosthetic joint infection as the primary endpoints.** One- and three-year cumulative incidences were 18.2% (95%CI 2.5%-45.5%) and 47.0% (95%CI 15.1%-74.0%), respectively, with all-cause revision of the APT as the endpoint. One- and three-year cumulative incidences were 10.0% (95%CI 0.5%-37.4%) and 44.0% (95%CI 6.3%-59.3%), respectively, with revision of APT due to periprosthetic joint infection as the endpoint. APT: All-polyethylene tibial; PJI: Periprosthetic joint infection.

with APTs over time, previous studies have paid little attention to the outcomes of tibial components until recently[6,9,20]. Bukowski *et al*[20] showed that DFRs with APT have a significantly lower incidence of tibial revision at 10 years (1.1% *vs* 12.5%, HR = 0.18, *P* = 0.03) and no difference in infection-free survival (*P* = 0.72) when compared to the traditional DFR with a metal backed tibia.

APT's are monoblock cemented components that offer cost-effectiveness and surgical efficiency when compared to metal-backed tibial components[21,22]. They avoid failure due to locking-mechanism issues and backside wear, but limit modularity and the option for late liner exchange. While we theorized that APTs would suffer from some of the same failure mechanisms as metal backed tibial components, such as periprosthetic joint infection and late polyethylene wear, it is unclear whether they exhibit novel modes of failure, or whether they are more resistant to certain types of failure, such as aseptic loosening, than metal-backed components. The purpose of this study was to examine a large cohort of DFR with APT performed for oncologic indications, with specific focus on failure rate and mechanisms of the APT.



DOI: 10.5312/wjo.v14.i4.218 Copyright ©The Author(s) 2023.

**Figure 4 Radiographs of a 58-year-old male patient showing increased lucency surrounding the proximal femoral stem with abutment of the lateral cortex.** A: Anteroposterior radiographs of the loosened distal femoral replacement; B: Interval explantation of the prior distal femoral replacement and placement of an intercalary cemented modular antibiotic spacer.

The most common modes of implant failure in this cohort were soft tissue (Type I) (10.9%) and deep infection (Type IV) (10.9%), followed by aseptic loosening (Type II) (9.1%). Aseptic loosening was evenly split between the femoral and tibial components. There were two revisions for corrosion and metal debris (Type III), and one case of tumor recurrence (Type V). The rate of infection is comparable to previous large series. Sharma demonstrated a 7.8% infection rate (Type IV), 6.5% local recurrence rate (Type V), and no aseptic loosening with line-to-line cemented femoral stems using the same implant system[23]. Henderson demonstrated 1.3% soft tissue failure (Type I), 6.4% aseptic loosening (Type II), 6.3% structural failure (Type III), and 8.3% infection (Type IV) in their cohort's subset of distal femur replacements[12]. Our soft tissue failure rate was significantly higher, for unclear reasons. Given the referral nature of our practice, the present cohort may be inherently at greater risk for soft tissue failure due to a higher proportion of ethnic minorities from underserved areas with greater comorbid burden, many of whom require prior insurance authorization resulting in delayed time to definitive treatment. However, rates of infection, aseptic loosening, and structural failure were similar. Pala demonstrated a 26.6% overall failure rate for DFRs in their study, including 6% soft tissue failure (Type I), 5% aseptic loosening (Type II), and 9% infection (Type IV)[24]. Our series of DFR with APT for oncologic indications appears to have similar modes and rates of failure as previously published studies. We demonstrated a higher rate of soft tissue failure, the reason for which is unclear. However, it is unlikely to be due to the APT, as the rotating tibial component and axel for the APT is approximately 2.5 cm longer for the APT than the metal-backed tibia, conferring a much larger jump distance prior to dislocation, i.e. soft tissue failure leading to instability[25].

Our study demonstrated a 24% revision rate and 47% all-cause reoperation rate at 3 years. This is consistent with large reports of modern distal femoral replacements[9]. The rate of aseptic loosening was 9.1%, which was seen on both the femoral and tibial side. This appears to be consistent with previous reports for femoral-sided aseptic loosening[12,24]. However, few reports have specifically examined the tibial component, so it is unclear how this rate of aseptic loosening of the tibial component (3/55) compares with other historical groups. One recent study suggests that these components achieve durable fixation, with no cases of aseptic loosening and a small number (6) sustaining mechanical failure of the tibial component out of 125 patients[8]. This speaks to the advantage of line-to-line cement technique on the femur, and durable fixation of the APT, with predictable long-term failure like our study. They also observed one patient with polyethylene granuloma over the APT. Finally, they noted an infection rate (Type IV failure) of 10%, nearly identical to our study, and reported a 15% reoperation rate at 1 year and 30% reoperation rate at 5 years.

Finally, we found no significant differences in terms of preoperative demographics or post-operative complications in patients who received DFR with APT as a primary or revision procedure for their oncologic process. The revision cohort had  $2.0 \pm 1.3$  (range 1-5) previous operations prior to DFR. It is surprising that the group performed as a revision procedure did not have a higher complication or reoperation rate, despite having been operated on previously. However, this finding is supported by several previous investigations. The reoperation rate of 38% in the revision DFR cohort is similar to published reports of DFR used for non-oncologic revision total knee arthroplasty, as the Mayo clinic series demonstrated a 46.3% percent all-cause reoperation rate at 10 years for non-oncologic DFR[26]. A similar reoperation rate was found by Staats and colleagues in a cohort of both oncologic and non-oncologic DFRs (36.4% at 2 years), and they were unable to detect a difference in the cumulative incidence of revision surgery in patients with oncologic *vs* non-oncologic disease[27]. Other studies have

found no difference between primary and revision DFRs as well[28,29], indicating that previous oncologic procedures in the same field do not significantly affect outcomes after DFR.

This study has several limitations. It is a single institution, retrospective study in which statistical power is limited due to sample size. Also, given the heterogeneity of oncologic disease, specific indications, treatments, and surgical techniques could not be standardized. However, the risk of unintentional selection bias in the present study is mitigated by the composition of the current cohort, which represents a consecutive series of DFR with APT performed for oncologic indications by a single surgeon at our institution. The APT was used consistently as the primary construct of the treating surgeon in this consecutive series of patients - therefore, we can only make historical comparisons to other studies, and cannot directly compare these patients with a cohort of metal-backed tibial components performed in the same patient population. These types of studies are difficult to accomplish in orthopaedic oncology due to the heterogeneous patient population and rare diseases treated. Nevertheless, the present study provides valuable insight into the survivorship and common modes of implant failure for the DFR with APT construct utilized this high-risk patient population, and there is value in reporting these case series so that they may be analyzed in aggregate with other published reports.

## CONCLUSION

Despite the inherent risk of complications and reoperations associated with oncologic surgery, DFR with APT is a reliable reconstructive option for oncologic defects of the distal femur. APTs are efficient, cost-effective, and more likely to avoid failure mechanisms related to modularity. Failures of DFR with APT, like other DFRs, are mostly related to infection, soft tissue failures, and late aseptic loosening. While we observed several cases of aseptic loosening of the tibial component, we did not observe fractures of the APT, which has been reported previously. In concordance with previous studies, we did not observe a difference in complication rates or failures between DFR with APT performed for primary and revision indications. Further studies, including cohort or randomized trials, are needed to determine the optimal tibial component for oncologic DFR.

## ARTICLE HIGHLIGHTS

### Research background

Future prospective studies with larger sample sizes and longer term followup are necessary to determine the optimal construct for oncologic distal femoral replacement (DFR). Comparative studies investigating the differences in clinical, functional, and patient-reported outcomes between the use of metal-backed *vs* all-polyethylene tibial components and cemented *vs* cementless fixation will provide further insight into the specific failure mechanisms associated with each construct.

### Research motivation

This study proposes that DFR with all-polyethylene tibial (APT) is a reliable reconstruction option for oncologic defects of the distal femur.

### Research objectives

DFR with APT implantation was performed as a primary procedure in 29 patients (52.7%) and a revision procedure in 26 patients (47.3%). Overall, twenty patients (36.4%) experienced a postoperative complication requiring reoperation. In total, 12 patients (21.8%) required a revision while 20 patients (36.4%) required a reoperation, resulting in three-year cumulative incidences of 24.0% (95% CI 9.9%-41.4%) and 47.2% (95% CI 27.5%-64.5%), respectively.

### Research methods

A retrospective review of consecutive patients who underwent DFR with a GMRS® (Global Modular Replacement System, Stryker, Kalamazoo, MI, United States) cemented distal femoral endoprosthesis and APT component for an oncologic indication was performed using a single-institutional database. Univariate analyses were performed to compare differences between those who had a DFR performed either as the primary treatment for the disease in question *vs* those who had a DFR as a revision of a previous failed surgery (indications included recurrence, fracture, *etc.*). Competing risk analyses were performed to evaluate the cumulative incidence of all-cause reoperation, need for revision surgery, and patient death.

### Research results

This study was designed to answer the following research questions: (1) What are the most common

modes of implant failure for patients undergoing cemented DFR with APT for oncologic indications? (2) What is the survivorship, rate of all-cause reoperation, and rate of revision for aseptic loosening of these implants? and (3) Is there a difference in implant survivorship or patient demographics between cemented DFRs with APT performed as a primary reconstruction *vs* those performed as a revision procedure?

### **Research conclusions**

Prior studies investigating the outcomes of endoprosthetic distal femoral replacement have largely failed to describe the type of tibial component or fixation used. Unlike the femoral component, tibial components are available in both metal-backed and all-polyethylene designs, and fixation may be achieved *via* cemented, cementless, or hybrid fixation. Future research investigating the effect of tibial component design and fixation on clinical outcomes is critical to determining the optimal construct for oncologic DFR.

### **Research perspectives**

Endoprosthetic reconstruction of the distal femur has been used as a limb-salvage procedure to treat oncologic processes of the distal femur for nearly five decades, and is currently considered standard of practice for this indication. However, there is a paucity of literature examining the survivorship of DFRs with respect to the type of tibial component utilized. The purpose of this study was to report on the clinical outcomes of patients undergoing cemented DFR with all-polyethylene tibial components for oncologic indications.

---

## **FOOTNOTES**

---

**Author contributions:** Christ AB, Menendez LR, and Heckmann ND generated the idea, provided guidance throughout, were heavily involved in copy-editing, and oversaw execution of the project; Chung BC, Urness M, Mayer L, and Gettleman BS were responsible for data collection, literature review, statistical analysis, and drafting the manuscript; All authors listed read and approved the final manuscript.

**Institutional review board statement:** Proposal #HS-20-00396 indicates that this study is determined to be IRB exempt.

**Informed consent statement:** The study is IRB-exempt at our institution because we did not employ the use of humans and the use of their protected health information for this study was deemed minimal risk. Thus, an Informed Consent form is not applicable for this study.

**Conflict-of-interest statement:** One of the authors (N.D.H.) is a paid consultant for Intellijoint Surgical and MicroPort Orthopedics, has stock options from Intellijoint Surgical, and is a committee member of AAOS and AJRR. One of the authors (L.R.M.) is a paid consultant for Onkos Surgical and receives IP royalties from TeDan Surgical. Each author certifies that he has no commercial associations that might pose a conflict of interest in connection with the submitted article. One of the authors (A.B.C.) is a board member for AAOS, Musculoskeletal Tumor Society, Orthopaedic Society. (A.B.C.) is also a paid consultant for Smith and Nephew, Intellijoint Surgical, and Enovis.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** United States

**ORCID number:** Alexander B Christ 0000-0002-0447-5762.

**S-Editor:** Liu JH

**L-Editor:** A

**P-Editor:** Yuan YY

## REFERENCES

- 1 **Simon MA**, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment vs amputation for osteosarcoma of the distal end of the femur. *J Bone Joint Surg Am* 1986; **68**: 1331-1337 [DOI: [10.2106/00004623-198668090-00005](https://doi.org/10.2106/00004623-198668090-00005)]
- 2 **Unwin PS**, Cannon SR, Grimer RJ, Kemp HB, Sneath RS, Walker PS. Aseptic loosening in cemented custom-made prosthetic replacements for bone tumours of the lower limb. *J Bone Joint Surg Br* 1996; **78**: 5-13 [PMID: [8898118](https://pubmed.ncbi.nlm.nih.gov/8898118/) DOI: [10.1302/0301-620X.78B1.0780005](https://doi.org/10.1302/0301-620X.78B1.0780005)]
- 3 **Schwartz AJ**, Kabo JM, Eilber FC, Eilber FR, Eckardt JJ. Cemented distal femoral endoprosthesis for musculoskeletal tumor: improved survival of modular versus custom implants. *Clin Orthop Relat Res* 2010; **468**: 2198-2210 [PMID: [20033359](https://pubmed.ncbi.nlm.nih.gov/20033359/) DOI: [10.1007/s11999-009-1197-8](https://doi.org/10.1007/s11999-009-1197-8)]
- 4 **Myers GJ**, Abudu AT, Carter SR, Tillman RM, Grimer RJ. Endoprosthetic replacement of the distal femur for bone tumours: long-term results. *J Bone Joint Surg Br* 2007; **89**: 521-526 [PMID: [17463123](https://pubmed.ncbi.nlm.nih.gov/17463123/) DOI: [10.1302/0301-620X.89B4.18631](https://doi.org/10.1302/0301-620X.89B4.18631)]
- 5 **Christ AB**, Hornicek FJ, Fabbri N. Distal femoral replacement - Cemented or cementless? *J Clin Orthop Trauma* 2021; **19**: 11-16 [PMID: [34040980](https://pubmed.ncbi.nlm.nih.gov/34040980/) DOI: [10.1016/j.jcot.2021.04.032](https://doi.org/10.1016/j.jcot.2021.04.032)]
- 6 **Pala E**, Mavrogenis AF, Angelini A, Henderson ER, Douglas Letson G, Ruggieri P. Cemented versus cementless endoprosthesis for lower limb salvage surgery. *J BUON* 2013; **18**: 496-503 [PMID: [23818368](https://pubmed.ncbi.nlm.nih.gov/23818368/)]
- 7 **Farfalli GL**, Boland PJ, Morris CD, Athanasian EA, Healey JH. Early equivalence of uncemented press-fit and Compress femoral fixation. *Clin Orthop Relat Res* 2009; **467**: 2792-2799 [PMID: [19513799](https://pubmed.ncbi.nlm.nih.gov/19513799/) DOI: [10.1007/s11999-009-0912-9](https://doi.org/10.1007/s11999-009-0912-9)]
- 8 **Tayara B**, Nooh A, Chalopin A, Goulding K, Turcotte RE. Outcomes of Cemented Distal Femoral Replacement Using "Line to Line" Technique With All-Polyethylene Tibial Implant for Tumors. *J Arthroplasty* 2021; **36**: 2913-2920 [PMID: [33840535](https://pubmed.ncbi.nlm.nih.gov/33840535/) DOI: [10.1016/j.arth.2021.03.033](https://doi.org/10.1016/j.arth.2021.03.033)]
- 9 **Ogura K**, Fujiwara T, Morris CD, Boland PJ, Healey JH. Long-term competing risks for overall and cause-specific failure of rotating-hinge distal femoral arthroplasty for tumour reconstruction. *Bone Joint J* 2021; **103-B**: 1405-1413 [PMID: [34334040](https://pubmed.ncbi.nlm.nih.gov/34334040/) DOI: [10.1302/0301-620X.103B8.BJJ-2020-2323.R1](https://doi.org/10.1302/0301-620X.103B8.BJJ-2020-2323.R1)]
- 10 **Haijie L**, Dasen L, Tao J, Yi Y, Xiaodong T, Wei G. Implant Survival and Complication Profiles of Endoprosthesis for Treating Tumor Around the Knee in Adults: A Systematic Review of the Literature Over the Past 30 Years. *J Arthroplasty* 2018; **33**: 1275-1287.e3 [PMID: [29191444](https://pubmed.ncbi.nlm.nih.gov/29191444/) DOI: [10.1016/j.arth.2017.10.051](https://doi.org/10.1016/j.arth.2017.10.051)]
- 11 **Graulich T**, Kranz C, Korallus C, Oergel M, Pacha OT, Omar M, Liodakis E, Krettek C, Panzica M. Clinical Outcome After Replacement of Distal Femur/Proximal Tibia in a Heterogeneous Patient Cohort: Function Following Tumour, Trauma, and Loosening. *In Vivo* 2021; **35**: 2275-2281 [PMID: [34182506](https://pubmed.ncbi.nlm.nih.gov/34182506/) DOI: [10.21873/invivo.12500](https://doi.org/10.21873/invivo.12500)]
- 12 **Henderson ER**, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, Windhager R, Kotz RI, Mercuri M, Funovics PT, Hornicek FJ, Temple HT, Ruggieri P, Letson GD. Failure mode classification for tumor endoprosthesis: retrospective review of five institutions and a literature review. *J Bone Joint Surg Am* 2011; **93**: 418-429 [PMID: [21368074](https://pubmed.ncbi.nlm.nih.gov/21368074/) DOI: [10.2106/JBJS.J.00834](https://doi.org/10.2106/JBJS.J.00834)]
- 13 **Therneau TM**, Grambsch PM. Modeling Survival Data: Extending the Cox Model. *SBH* 2000 [DOI: [10.1007/978-1-4757-3294-8](https://doi.org/10.1007/978-1-4757-3294-8)]
- 14 **Therneau T**. A package for survival analysis in R: R package version 3.2-10. 2021. 2021 [DOI: [10.2172/1762702](https://doi.org/10.2172/1762702)]
- 15 **Gray B**. cmprsk: subdistribution analysis of competing risks. 2014. R package version 2020; 2-1
- 16 **Ripley BD**. The R project in statistical computing. *MSOR Connect* 2001; **1**: 23-25 [DOI: [10.11120/msor.2001.01010023](https://doi.org/10.11120/msor.2001.01010023)]
- 17 **Wickham H**. ggplot2: Elegant Graphics for Data Analysis. Springer International Publishing [DOI: [10.1007/978-0-387-98141-3](https://doi.org/10.1007/978-0-387-98141-3)]
- 18 **Team RC**. R: A language and environment for statistical computing (R Version 4.0.3, R Foundation for Statistical Computing, Vienna, Austria, 2020). 2021 [DOI: [10.1007/978-1-4612-4214-7\\_1](https://doi.org/10.1007/978-1-4612-4214-7_1)]
- 19 **Houdek MT**, Wagner ER, Wilke BK, Wyles CC, Taunton MJ, Sim FH. Long term outcomes of cemented endoprosthetic reconstruction for periarticular tumors of the distal femur. *Knee* 2016; **23**: 167-172 [PMID: [26362940](https://pubmed.ncbi.nlm.nih.gov/26362940/) DOI: [10.1016/j.knee.2015.08.010](https://doi.org/10.1016/j.knee.2015.08.010)]
- 20 **Bukowski BR**, Tagliero AJ, Heidenreich MJ, Johnson JD, Rose PS, Houdek MT. Comparison of all-polyethylene and metal-backed modular tibial components in endoprosthetic reconstruction of the distal femur. *J Surg Oncol* 2021; **123**: 1126-1133 [PMID: [33373471](https://pubmed.ncbi.nlm.nih.gov/33373471/) DOI: [10.1002/jso.26358](https://doi.org/10.1002/jso.26358)]
- 21 **Ryan SP**, Steele JR, Plate JF, Attarian DE, Seyler TM, Bolognesi MP, Wellman SS. All-Polyethylene Tibia: An Opportunity for Value-Based Care in Bundled Reimbursement Initiatives. *Orthopedics* 2021; **44**: e114-e118 [PMID: [33141229](https://pubmed.ncbi.nlm.nih.gov/33141229/) DOI: [10.3928/01477447-20201009-01](https://doi.org/10.3928/01477447-20201009-01)]
- 22 **Kumar V**, Hasan O, Umer M, Baloch N. Cemented all-poly tibia in resource constrained country, affordable and cost-effective care. Is it applicable at this era? *Ann Med Surg (Lond)* 2019; **47**: 36-40 [PMID: [31641501](https://pubmed.ncbi.nlm.nih.gov/31641501/) DOI: [10.1016/j.amsu.2019.09.010](https://doi.org/10.1016/j.amsu.2019.09.010)]
- 23 **Sharma S**, Turcotte RE, Isler MH, Wong C. Cemented rotating hinge endoprosthesis for limb salvage of distal femur tumors. *Clin Orthop Relat Res* 2006; **450**: 28-32 [PMID: [16906068](https://pubmed.ncbi.nlm.nih.gov/16906068/) DOI: [10.1097/01.bl0.0000229316.66501.fc](https://doi.org/10.1097/01.bl0.0000229316.66501.fc)]
- 24 **Pala E**, Henderson ER, Calabrò T, Angelini A, Abati CN, Trovarelli G, Ruggieri P. Survival of current production tumor endoprosthesis: complications, functional results, and a comparative statistical analysis. *J Surg Oncol* 2013; **108**: 403-408 [PMID: [24006247](https://pubmed.ncbi.nlm.nih.gov/24006247/) DOI: [10.1002/jso.23414](https://doi.org/10.1002/jso.23414)]
- 25 **Ward WG**, Haight D, Ritchie P, Gordon S, Eckardt JJ. Dislocation of rotating hinge total knee prostheses. A biomechanical analysis. *J Bone Joint Surg Am* 2003; **85**: 448-453 [PMID: [12637430](https://pubmed.ncbi.nlm.nih.gov/12637430/) DOI: [10.2106/00004623-200303000-00008](https://doi.org/10.2106/00004623-200303000-00008)]
- 26 **Wyles CC**, Tibbo ME, Yuan BJ, Trousdale RT, Berry DJ, Abdel MP. Long-Term Results of Total Knee Arthroplasty with Contemporary Distal Femoral Replacement. *J Bone Joint Surg Am* 2020; **102**: 45-51 [PMID: [31596808](https://pubmed.ncbi.nlm.nih.gov/31596808/) DOI: [10.2106/JBJS.19.00489](https://doi.org/10.2106/JBJS.19.00489)]
- 27 **Staats K**, Vertesich K, Sigmund IK, Sosa B, Kaider A, Funovics PT, Windhager R. Does a Competing Risk Analysis Show Differences in the Cumulative Incidence of Revision Surgery Between Patients with Oncologic and Non-oncologic

- Conditions After Distal Femur Replacement? *Clin Orthop Relat Res* 2020; **478**: 1062-1073 [PMID: 31895069 DOI: 10.1097/CORR.0000000000001106]
- 28 **Heyberger C**, Auberger G, Babinet A, Anract P, Biau DJ. Patients with Revision Modern Megaprotheses of the Distal Femur Have Improved Disease-Specific and Health-Related Outcomes Compared to Those with Primary Replacements. *J Knee Surg* 2018; **31**: 822-826 [PMID: 29270950 DOI: 10.1055/s-0037-1615298]
- 29 **Zimel MN**, Farfalli GL, Zindman AM, Riedel ER, Morris CD, Boland PJ, Healey JH. Revision Distal Femoral Arthroplasty With the Compress(®) Prosthesis Has a Low Rate of Mechanical Failure at 10 Years. *Clin Orthop Relat Res* 2016; **474**: 528-536 [PMID: 26394638 DOI: 10.1007/s11999-015-4552-y]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

